Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast (ROMANCE)

January 22, 2026 updated by: UNICANCER

Prospective Study of Omission of Whole-breast Radiotherapy Following Breast-conserving Surgery in Patients With Very Low Risk Ductal Carcinoma in Situ of the Breast

Following breast-conserving surgery (BCS) for localized ductal carcinoma in situ (DCIS) of the breast, whole-breast irradiation (WBRT) is a standard of care, reducing the absolute rate of in-breast recurrences (IBR) by more than 15% at 10 years, from 28% without radiotherapy to 13 % with radiotherapy. Half of the recurrences occurred as invasive disease. Whereas in the comparative trials, WBRT did not impact on overall survival, survival of patients who recurred with invasive cancers was impaired in comparison to patients who did not recur, or to patients with DCIS-only recurrences.

Using criteria based on age, tumor size, nuclear grade, and margins status, several trials and cohort studies failed to identify subgroups of patients at low risk, who could be safely spared the need for WBRT. The Radiation Therapy Oncology Group (RTOG) DCIS trial included patients treated with BCS for low- or intermediate grade DCIS revealed by unifocal microcalcifications, size ≤25 mm, margins ≥3 mm, and no residual microcalcifications after surgery. The 5-year rates of IBR were 3.5 % without radiotherapy, versus 0.4 % with radiotherapy, and 6.7 % and 0.9 % at 7 years, respectively (p <0.001). Sixty percent of the patients received tamoxifen in both groups.

Several studies showed that the same molecular classes were identified in DCIS as in invasive cancers. Studies suggested that low proliferation, hormone receptors expression, and lack of ERBB2 amplification were associated with a low risk of IBR in patients not receiving radiotherapy. A combined signature was tested in the Eastern Cooperative Oncology Group (ECOG) trial, showing a 10% IBR rate at ten years in patients with a low-risk.

Identifying very low-risk DCIS, using biological markers in addition to the clinical and histological markers of low-risk DCIS, could help to select patients who could be safely avoided WBRT following BCS. It would avoid over-treatment in these women and could decrease the cost of management.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

295

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Angers, France
        • Institut de Cancérologie de l'Ouest -Site Paul Papin
      • Avignon, France
        • Institut Sainte Catherine
      • Bayonne, France
        • Clinique Belharra
      • Bayonne, France
        • Centre d'Oncologie et de Radiotherapie du pays Basque
      • Bordeaux, France
        • Institut Bergonie
      • Caen, France
        • Centre François Baclesse
      • Cherbourg, France
        • centre hospitalier du Cotentin
      • Clermont-Ferrand, France
        • Centre Jean Perrin
      • Créteil, France
        • Hopital Henri Mondor
      • Créteil, France
        • CHIC Créteil
      • Dijon, France
        • Centre Georges François Leclerc
      • Jossigny, France
        • Centre Hospitalier De Lagny Sur Marne
      • La Réunion, France
        • CHU Saint-Pierre La Réunion
      • Le Havre, France
        • Centre Guillaume Le Conquérant
      • Lille, France
        • Centre Oscar Lambret
      • Limoges, France
        • CHU de Limoges - Hopital Dupuytren
      • Lorient, France
        • Centre Hospitalier Bretagne Sud
      • Lyon, France
        • Centre Léon Bérard
      • Lyon, France
        • Centre de Radiothérapie Mermoz
      • Lyon, France
        • Hôpital La Croix Rousse
      • Montpellier, France
        • Institut Regional Du Cancer Montpellier Val D Aurelle
      • Mougins, France
        • Centre Azuréen de Cancérologie
      • Nice, France
        • Centre Antoine Lacassagne
      • Nice, France
        • Centre de Haute Energie
      • Paris, France
        • Hôpital Pitie Salpétrière
      • Paris, France
        • Institut Curie
      • Pierre-Bénite, France
        • Centre Hospitalier LYON SUD
      • Reims, France
        • Institut Jean Godinot
      • Rennes, France
        • Centre Eugene Marquis
      • Rouen, France
        • Centre Frédéric Joliot
      • Saint-Cloud, France
        • Hôpital René Huguenin - Institut Curie
      • Saint-Etienne, France
        • Chu Saint-Etienne
      • Strasbourg, France
        • Centre Paul Strauss
      • Strasbourg, France
        • Centre de Radiothérapie de la Robertsau
      • Toulouse, France
        • Institut Claudius Regaud
      • Vandœuvre-lès-Nancy, France
        • Institut de Cancérologie de Lorraine ALEXIS VAUTRIN
      • Villejuif, France
        • Gustave Roussy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Woman aged ≥50 years,
  2. ECOG performance status ≤2
  3. Microcalcifications on pre-biopsy mammography, unifocal, ≤25 mm or opacity without microcalcifications and no clinical palpable tumour
  4. Absence of suspicious residual microcalcifications either on post-biopsy/ preoperative localization mammography, or on post-operative mammography Note: if absence of residual microcalcifications on post-biopsy/pre-operative mammography, post-operative mammography is not mandatory;
  5. Breast-conserving surgical excision;
  6. Histologically proven DCIS of the breast without an invasive component; Note Incidental histological finding of DCIS lesions developed within a benign breast lesion as well as an association with classical lobular carcinoma in situ (LCIS) associated with the DCIS are accepted.
  7. Free margins (≥2 mm), or free margins following re-excision;
  8. Low or Intermediate nuclear grade; Note: In case of nuclear grade heterogeneity within the same sample or between the biopsy or the surgical specimen, the highest nuclear grade score will prevail.
  9. Tumour tissue sample availability; Note: Surgical specimen is mandatory unless no residual disease on the surgical specimen. In this instance, the initial diagnosis biopsy is required.
  10. Absence of extensive necrosis (≤30% of the lumen diameter);
  11. Immunohistochemical characteristics of luminal A subtype: ER≥10 %, PR ≥20 %, HER2 negative (0/1+) or 2+ not amplified (confirmed by fluorescent in situ hybridization (FISH) or chromogenic in situ hybridization (CISH)), Ki67 <15%.
  12. Patient willing and able to comply with the protocol for the duration of the study including undergoing treatment, scheduled visits and examinations and including follow-up;
  13. Written informed consent.
  14. Affiliation to the French social security.

Exclusion Criteria:

  1. Endocrine treatment for breast cancer.
  2. Previous invasive breast cancer including contralateral breast cancer, either metachronous or synchronous
  3. Previous DCIS except contralateral DCIS in complete and continuous remission for more than 5 years
  4. Previous other cancers (except basal-cell, carcinoma in situ of the cervix or endometrium), not in complete and continuous remission for more than 10 years
  5. Known breast-cancer predisposing germ-cell mutation;
  6. Palpable tumour with a diagnosis of DCIS on biopsy
  7. Bloody nipple discharge;
  8. Histological size >25 mm in one or multiple foci
  9. High nuclear grade, including high nuclear grade in heterogeneous tumours;either on biopsy or on surgical specimen
  10. Associated microinvasive or invasive component;
  11. Presence of tumour cells in lymph nodes detected using H&E or immunohistochemical examination (if lymph node sentinel biopsy or dissection has been performed);
  12. Absolute contra-indication to whole-breast irradiation as determined by the referring physician;
  13. Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study.
  14. Pregnant women or breast feeding mothers,

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Radiotherapy
two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
Experimental: No Radiotherapy
No Irradiation- Active surveillance
No Irradiation- Active surveillance

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
5-year cumulative incidence of in-breast cancer recurrences
Time Frame: 5 years
Incidence of breast recurrence is determined from the date of last surgery to the date of breast recurrence.
5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival (OS)
Time Frame: 10 years
OS is defined as the interval between the date of last surgery and the date of death from any cause;
10 years
Breast cancer-specific survival (BCSS)
Time Frame: 10 years
BCSS is defined as the interval between the date of last surgery and the date of death from breast cancer
10 years
Relapse-free survival (RFS)
Time Frame: 10 years
RFS is defined as the interval between the date of last surgery and the date of ipsilateral breast recurrence, regional nodes recurrence, distant metastases, of death from breast cancer, whichever occurs first
10 years
Rate of in-breast recurrences (IBR).
Time Frame: 10 years
In-breast recurrence defined as any carcinoma (invasive or in situ) occurring in the treated breast
10 years
Rate of Contralateral breast
Time Frame: 10 years
Contralateral breast cancer defined as any carcinoma (invasive or in situ) occurring in the contralateral breast.
10 years
Quality of life of the patients using EORTC-QLQ-C 30
Time Frame: 3 years
Quality of life will be assessed using QLQ-C 30 questionnaire from the European Organization for Research and Treatment of Cancer (EORTC). It is a 30-item self-reporting questionnaire developed to assess the quality of life of cancer patients. It is grouped into five functional subscales (role, physical, cognitive, emotional and social functioning). In addition, there are three multi-item symptom scales (fatigue, pain, and nausea and vomiting), individual questions concerning common symptoms in cancer patients,and two questions assessing overall Quality of Life
3 years
Quality of life of the patients using EORTC-QLQ-BR23
Time Frame: 3 years
Quality of Life of Patients will be assessed using a EORTC-QLQ BR23.It is a 23-item self-reporting specific questionnaire developed to assess the quality of life of breast cancer patients. It permits to evaluate the symptoms of breast cancer and the side effects of treatment.
3 years
Cosmetics Evaluation
Time Frame: 3 years
cosmetic results will be evaluated by centralized photographic analysis.
3 years
Long term toxicities
Time Frame: Throughout study completion, up to 10 years.
The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders and so the late effects and sequelea regarding the whole-breast radiotherapy.
Throughout study completion, up to 10 years.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Alain FOURQUET, MD, Institut Curie

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 10, 2019

Primary Completion (Estimated)

November 14, 2029

Study Completion (Estimated)

November 14, 2034

Study Registration Dates

First Submitted

March 14, 2019

First Submitted That Met QC Criteria

March 14, 2019

First Posted (Actual)

March 18, 2019

Study Record Updates

Last Update Posted (Actual)

January 23, 2026

Last Update Submitted That Met QC Criteria

January 22, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • UC-0107/1803

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.